CervoMed Inc. announced on April 18, 2025, several changes to its executive leadership team. Kelly Blackburn, M.H.A., was appointed Executive Vice President, Clinical Development, effective April 16, 2025, a promotion from her previous role as Senior Vice President.
Mark De Rosch, Ph.D., FRAPS, was appointed Executive Vice President, Regulatory and Government Affairs and Program Management, effective May 1, 2025, also an elevation from his prior Senior Vice President position. These promotions aim to strengthen key areas of the company's operations.
Additionally, Robert J. Cobuzzi, Jr., Ph.D., the company’s Chief Operating Officer, will conclude his employment with CervoMed effective July 1, 2025. Dr. Cobuzzi will also not stand for re-election to the Board of Directors, with his current term ending at the 2025 Annual Meeting of Stockholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.